High Diagnostic Ability of Multiparametric Magnetic Resonance Imaging to Detect Anterior Prostate Cancer Missed by Transrectal 12-Core Biopsy

Komai, Yoshinobu; Numao, Noboru; Yoshida, Soichiro; Matsuoka, Yoh; Nakanishi, Yasukazu; Ishii, Chikako; Koga, Fumitaka; Saito, Kazutaka; Masuda, Hitoshi; Fujii, Yasuhisa; Kawakami, Satoru; Kihara, Kazunori

doi:10.1016/j.juro.2013.03.078

Cited by 64 publications

(45 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A total of 8663 original studies in English were identified and 15 were analyzed. [2][3][4][6][7][8][23][24][25][26][27][28][29][30][31] The overall quality varied from low to moderate. Fourteen conference abstracts will require followup in future updated versions.…”

Section: Literature Search Resultsmentioning

confidence: 99%

“…• In two studies 23,25 with a prevalence of CSPC of 21-30%, the ranges of sensitivity, specificity, positive predictive value, and negative predictive value of mpPMRI to detect CSPC were 68-94%, 21-72%, 24-50%, and 83-94%, respectively.…”

Section: Key Evidencementioning

confidence: 98%

“…• Eight eligible studies 2,3,6,7,[23][24][25][26] addressed the first objective. The quality of evidence ranged from poor to moderate.…”

Section: Key Evidencementioning

confidence: 99%

See 2 more Smart Citations

Evidence-based guideline recommendations on multiparametric magnetic resonance imaging in the diagnosis of prostate cancer: A Cancer Care Ontario clinical practice guideline

Haider

Yao

Loblaw

et al. 2017

CUAJ

View full text Add to dashboard Cite

Cite as: Can Urol Assoc J 2017;11(1-2):E1-7. http://dx.doi.org/10.5489/cuaj.3968 Published online January 12, 2017 AbstractThis clinical guideline focuses on: 1) the use of multiparametric magnetic resonance imaging (mpMRI) in diagnosing clinically significant prostate cancer (CSPC) in patients with an elevated risk of CSPC and who are biopsy-naïve; and 2) the use of mpMRI in diagnosing CSPC in patients with a persistently elevated risk of having CSPC and who have a negative transrectal ultrasound (TRUS)-guided systematic biopsy.

show abstract

Section: Literature Search Resultsmentioning

confidence: 99%

Section: Key Evidencementioning

confidence: 98%

See 1 more Smart Citation

Evidence-based guideline recommendations on multiparametric magnetic resonance imaging in the diagnosis of prostate cancer: A Cancer Care Ontario clinical practice guideline

Haider

Yao

Loblaw

et al. 2017

CUAJ

View full text Add to dashboard Cite

show abstract

“…Recently, Al-Ahmadie et al [14] in 1,312 radical prostatectomies demonstrated that 197 (15%) PCa were located in the AZ of the gland and characterized by a superimposable grading and staging in comparison with PZ PCa; Iremashvili et al [22] reported a higher rate of positive surgical margin in the presence of TZ cancer in comparison with PZ PCa in 1,141 men submitted to radical prostatectomy. In the last years, magnetic resonance imaging and magnetic resonance imaging/ultrasound fusion-guided biopsy have increased the detection of PCa at repeat biopsy, with an estimated incidence equal to 30-50% of cases [5,6,7]; in this respect, transperineal prostate biopsy demonstrated a better accuracy in comparison with the transrectal approach in the diagnosis of AZ cancers [23]. On the other hand, still today the incidence and clinical relevance of AZ cancers diagnosed in case of initial prostate biopsy are unknown.…”

Section: Discussionmentioning

confidence: 99%

Detection Rate of Anterior Prostate Cancer in 226 Patients Submitted to Initial and Repeat Transperineal Biopsy

et al. 2014

View full text Add to dashboard Cite

Objective: To evaluate the detection rate of anterior zone (AZ) prostate cancer (PCa) in patients submitted to initial and repeat transperineal prostate biopsy. Methods: From January 2013 to August 2013, 226 patients (median age 64 years) with negative digital rectal examination underwent initial (144 cases) and repeat (82 cases) transperineal prostate biopsy for PSA >10 ng/ml, PSA 4.1-10.0 or 2.6-4.0 ng/ml with free/total PSA ≤25% and ≤20%, respectively. A median of 22 versus 32 cores were performed, including 4 cores of the AZ versus 6 cores (4 anterior plus 2 cores of the transition zone, TZ) at initial versus repeat biopsy, respectively. The detection rate of PCa of the peripheral zone (PZ), AZ and TZ was prospectively evaluated. Results: The median PSA was 7.6 ng/ml; overall, a stage cT1c PCa was found in 104/226 (46%) patients, in 70 (48.6%) and 34 (41.5%) of the men who underwent initial and repeat biopsy, respectively. An AZ PCa was found in 11.5 vs. 8.8% (p = 0.32) of the patients submitted to initial versus repeat biopsy, respectively. AZ cancers demonstrated a number of positive cores (p = 0.03), greatest percentage of cancer (p = 0.001) and total percentage of cancer (p = 0.001) significantly lower in comparison with PZ PCa; moreover, 56.2 vs. 36.5% of AZ versus PZ PCa were characterized by a microfocus of cancer (p = 0.001), respectively. Conclusions: AZ biopsies increase the detection rate of PCa (about 10% of cases) at initial and repeat biopsy, allowing reduction of the biopsy false-negative rate.

show abstract

“…Among the 15 studies, one was an RCT [55], five were prospective studies [2,56,57,60,65], six were retrospective studies [3,59,61e64] and three did not report their study designs [54,58,66] (Table 1).…”

Section: Study Design and Qualitymentioning

confidence: 99%

Multiparametric Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer: A Systematic Review

et al. 2016

View full text Add to dashboard Cite

High Diagnostic Ability of Multiparametric Magnetic Resonance Imaging to Detect Anterior Prostate Cancer Missed by Transrectal 12-Core Biopsy

Abstract: Prebiopsy multiparametric magnetic resonance imaging has the potential to efficiently select men who could advantageously undergo anterior samplings, in addition to transrectal 12-core prostate biopsy.

Cited by 64 publications

References 25 publications

Evidence-based guideline recommendations on multiparametric magnetic resonance imaging in the diagnosis of prostate cancer: A Cancer Care Ontario clinical practice guideline

Evidence-based guideline recommendations on multiparametric magnetic resonance imaging in the diagnosis of prostate cancer: A Cancer Care Ontario clinical practice guideline

Detection Rate of Anterior Prostate Cancer in 226 Patients Submitted to Initial and Repeat Transperineal Biopsy

Multiparametric Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer: A Systematic Review

Contact Info

Product

Resources

About